Excessive dopamine neuron loss in progressive supranuclear palsy
Identifieur interne : 002853 ( Main/Exploration ); précédent : 002852; suivant : 002854Excessive dopamine neuron loss in progressive supranuclear palsy
Auteurs : Karen E. Murphy [Australie] ; Tanya Karaconji [Australie] ; Craig D. Hardman [Australie] ; Glenda M. Halliday [Australie]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-03-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Cell death, Disease Progression, Dopamine, Dopamine (deficiency), Dopamine (metabolism), Dopamine Agonists (therapeutic use), Female, Humans, Levodopa (therapeutic use), Male, Midbrain, Nerve Degeneration (metabolism), Nervous system diseases, Neuron, Neurons (metabolism), Neurons (pathology), Parkinson disease, Parkinson's disease, Substantia Nigra (metabolism), Substantia Nigra (pathology), Supranuclear Palsy, Progressive (drug therapy), Supranuclear Palsy, Progressive (metabolism), Supranuclear Palsy, Progressive (pathology), dopamine neurons, midbrain, neurodegeneration, progressive supranuclear palsy.
- MESH :
- chemical , deficiency : Dopamine.
- chemical , metabolism : Dopamine.
- chemical , therapeutic use : Dopamine Agonists, Levodopa.
- drug therapy : Supranuclear Palsy, Progressive.
- metabolism : Nerve Degeneration, Neurons, Substantia Nigra, Supranuclear Palsy, Progressive.
- pathology : Neurons, Substantia Nigra, Supranuclear Palsy, Progressive.
- Aged, Disease Progression, Female, Humans, Male.
Abstract
Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21907
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003339
- to stream Istex, to step Curation: 003339
- to stream Istex, to step Checkpoint: 001409
- to stream PubMed, to step Corpus: 002368
- to stream PubMed, to step Curation: 002368
- to stream PubMed, to step Checkpoint: 002303
- to stream Ncbi, to step Merge: 001F91
- to stream Ncbi, to step Curation: 001F91
- to stream Ncbi, to step Checkpoint: 001F91
- to stream Main, to step Merge: 003431
- to stream PascalFrancis, to step Corpus: 001298
- to stream PascalFrancis, to step Curation: 001A21
- to stream PascalFrancis, to step Checkpoint: 001259
- to stream Main, to step Merge: 003867
- to stream Main, to step Curation: 002853
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Excessive dopamine neuron loss in progressive supranuclear palsy</title><author><name sortKey="Murphy, Karen E" sort="Murphy, Karen E" uniqKey="Murphy K" first="Karen E." last="Murphy">Karen E. Murphy</name></author><author><name sortKey="Karaconji, Tanya" sort="Karaconji, Tanya" uniqKey="Karaconji T" first="Tanya" last="Karaconji">Tanya Karaconji</name></author><author><name sortKey="Hardman, Craig D" sort="Hardman, Craig D" uniqKey="Hardman C" first="Craig D." last="Hardman">Craig D. Hardman</name></author><author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:586B0C1676F261AD729ED5E7E561C072A5D2E344</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21907</idno><idno type="url">https://api.istex.fr/document/586B0C1676F261AD729ED5E7E561C072A5D2E344/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003339</idno><idno type="wicri:Area/Istex/Curation">003339</idno><idno type="wicri:Area/Istex/Checkpoint">001409</idno><idno type="wicri:doubleKey">0885-3185:2008:Murphy K:excessive:dopamine:neuron</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18163454</idno><idno type="wicri:Area/PubMed/Corpus">002368</idno><idno type="wicri:Area/PubMed/Curation">002368</idno><idno type="wicri:Area/PubMed/Checkpoint">002303</idno><idno type="wicri:Area/Ncbi/Merge">001F91</idno><idno type="wicri:Area/Ncbi/Curation">001F91</idno><idno type="wicri:Area/Ncbi/Checkpoint">001F91</idno><idno type="wicri:Area/Main/Merge">003431</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0199373</idno><idno type="wicri:Area/PascalFrancis/Corpus">001298</idno><idno type="wicri:Area/PascalFrancis/Curation">001A21</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001259</idno><idno type="wicri:doubleKey">0885-3185:2008:Murphy K:excessive:dopamine:neuron</idno><idno type="wicri:Area/Main/Merge">003867</idno><idno type="wicri:Area/Main/Curation">002853</idno><idno type="wicri:Area/Main/Exploration">002853</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Excessive dopamine neuron loss in progressive supranuclear palsy</title><author><name sortKey="Murphy, Karen E" sort="Murphy, Karen E" uniqKey="Murphy K" first="Karen E." last="Murphy">Karen E. Murphy</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Prince of Wales Medical Research Institute, Randwick</wicri:regionArea><wicri:noRegion>Randwick</wicri:noRegion></affiliation></author><author><name sortKey="Karaconji, Tanya" sort="Karaconji, Tanya" uniqKey="Karaconji T" first="Tanya" last="Karaconji">Tanya Karaconji</name><affiliation wicri:level="3"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Anatomy, School of Medical Sciences, University of New South Wales, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement></placeName></affiliation></author><author><name sortKey="Hardman, Craig D" sort="Hardman, Craig D" uniqKey="Hardman C" first="Craig D." last="Hardman">Craig D. Hardman</name><affiliation wicri:level="3"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Anatomy, School of Medical Sciences, University of New South Wales, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement></placeName></affiliation></author><author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Prince of Wales Medical Research Institute, Randwick</wicri:regionArea><wicri:noRegion>Randwick</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-03-15">2008-03-15</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="607">607</biblScope><biblScope unit="page" to="610">610</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">586B0C1676F261AD729ED5E7E561C072A5D2E344</idno><idno type="DOI">10.1002/mds.21907</idno><idno type="ArticleID">MDS21907</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Cell death</term><term>Disease Progression</term><term>Dopamine</term><term>Dopamine (deficiency)</term><term>Dopamine (metabolism)</term><term>Dopamine Agonists (therapeutic use)</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Midbrain</term><term>Nerve Degeneration (metabolism)</term><term>Nervous system diseases</term><term>Neuron</term><term>Neurons (metabolism)</term><term>Neurons (pathology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Substantia Nigra (metabolism)</term><term>Substantia Nigra (pathology)</term><term>Supranuclear Palsy, Progressive (drug therapy)</term><term>Supranuclear Palsy, Progressive (metabolism)</term><term>Supranuclear Palsy, Progressive (pathology)</term><term>dopamine neurons</term><term>midbrain</term><term>neurodegeneration</term><term>progressive supranuclear palsy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Nerve Degeneration</term><term>Neurons</term><term>Substantia Nigra</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neurons</term><term>Substantia Nigra</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term><term>Maladie de Parkinson</term><term>Mort cellulaire</term><term>Mésencéphale</term><term>Neurone</term><term>Pathologie du système nerveux</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Australie</li></country><settlement><li>Sydney</li></settlement></list><tree><country name="Australie"><noRegion><name sortKey="Murphy, Karen E" sort="Murphy, Karen E" uniqKey="Murphy K" first="Karen E." last="Murphy">Karen E. Murphy</name></noRegion><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name><name sortKey="Hardman, Craig D" sort="Hardman, Craig D" uniqKey="Hardman C" first="Craig D." last="Hardman">Craig D. Hardman</name><name sortKey="Karaconji, Tanya" sort="Karaconji, Tanya" uniqKey="Karaconji T" first="Tanya" last="Karaconji">Tanya Karaconji</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002853 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002853 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:586B0C1676F261AD729ED5E7E561C072A5D2E344
|texte= Excessive dopamine neuron loss in progressive supranuclear palsy
}}
| This area was generated with Dilib version V0.6.23. |  |